Deutsch English Français

Contact

EP0752853

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP0752853

EP0752853 - HUMAN BRAIN PHOSPHODIESTERASE [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 28.07.2006 Database last updated on 26.07.2024
Most recent event Tooltip	28.07.2006	No opposition filed within time limit	published on 30.08.2006 [2006/35]
Applicant(s)	For all designated states SMITHKLINE BEECHAM CORPORATION One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 / US
	[N/P]
Former [2005/38]	For all designated states SMITHKLINE BEECHAM CORPORATION One Franklin Plaza, P.O. Box 7929 Philadelphia, Pennsylvania 19101 / US
Former [2005/15]	For all designated states SMITHKLINE BEECHAM CORPORATION One Franklin Plaza, P.O. Box 7929 Philadelphia, Pennsylvania 19101 / US
Former [1997/03]	For all designated states SMITHKLINE BEECHAM CORPORATION UW2220, 709 Swedeland Road, P.O. Box 1539 King of Prussia, PA 19406-0939 / US
Inventor(s)	01 / LIVI, George P. 33 E. Langhorne Avenue Havertown, PA 19083 / US
	02 / Mc LAUGHLIN, Megan, M. 2505 Mansfield Avenue Drexel Hill, PA 19026 / US
	03 / TORPHY, Theodore J. 421 Shortridge Drive Wynnewood, PA 19096 / US
	[1997/03]
Representative(s)	Rutter, Keith, et al GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB
	[N/P]
Former [2005/15]	Rutter, Keith, Dr., et al GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB
Former [1997/03]	Rutter, Keith, Dr. SmithKline Beecham plc Corporate Intellectual Property, Two New Horizons Court Brentford, Middlesex TW8 9EP / GB
Application number, filing date	94911544.8	10.03.1994
	[1997/03]
	WO1994US02612
Priority number, date	US19930029334	10.03.1993 Original published format: US 29334
	[1997/03]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO9420079
	Date:	15.09.1994
	Language:	EN
	[1994/21]
	Type:	A1 Application with search report
	No.:	EP0752853
	Date:	15.01.1997
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 15.09.1994 takes the place of the publication of the European patent application.
	[1997/03]
	Type:	B1 Patent specification
	No.:	EP0752853
	Date:	21.09.2005
	Language:	EN
	[2005/38]
Search report(s)	International search report - published on:	US	15.09.1994
	(Supplementary) European search report - dispatched on:	EP	02.06.1997
Classification	IPC:	C12N15/55, C12N9/16, C12N15/81, C12N1/19, C12Q1/44, A61K31/00, C07K14/47	[2005/38]
	CPC:	C12N9/16 (EP,US)
	Former IPC [1997/29]	C12N15/55, C12N9/16, C12N15/81, C12N1/19, C12Q1/44, A61K31/00, C07K15/28
	Former IPC [1997/03]	A61K31/00, C07H21/00, C07K15/00, C07K15/28, C12N1/19, C12N1/21, C12N5/10, C12N9/16, C12N15/55, C12Q1/44
Designated contracting states	BE, CH, DE, FR, GB, IT, LI, NL [1997/03]
Title	German:	PHOSPHODIESTERASE DES MENSCHLICHEN GEHIRNS	[1997/03]
	English:	HUMAN BRAIN PHOSPHODIESTERASE	[1997/03]
	French:	PHOSPHODIESTERASE DU CERVEAU HUMAIN	[2004/44]
	Former [1997/03]	PPHOSPHODIESTERASE DU CERVEAU HUMAIN
Entry into regional phase	12.09.1995	National basic fee paid
	12.09.1995	Search fee paid
	12.09.1995	Designation fee(s) paid
	12.09.1995	Examination fee paid
Examination procedure	24.08.1994	Request for preliminary examination filed International Preliminary Examining Authority: US
	12.09.1995	Examination requested [1997/03]
	24.08.1999	Despatch of a communication from the examining division (Time limit: M06)
	02.03.2000	Reply to a communication from the examining division
	02.03.2000	Request for accelerated examination filed
	11.04.2000	Despatch of a communication from the examining division (Time limit: M04)
	09.08.2000	Reply to a communication from the examining division
	13.12.2000	Despatch of a communication from the examining division (Time limit: M04)
	07.03.2001	Reply to a communication from the examining division
	19.03.2002	Date of oral proceedings
	31.05.2002	Despatch of communication that the application is refused, reason: substantive examination {1}
	31.05.2002	Minutes of oral proceedings despatched
	07.10.2004	Communication of intention to grant the patent
	07.10.2004	Decision about request for accelerated examination - accepted: Yes
	14.12.2004	Fee for grant paid
	14.12.2004	Fee for publishing/printing paid
Appeal following examination	19.07.2002	Appeal received No. T0182/03
	08.10.2002	Statement of grounds filed
	23.06.2004	Result of appeal procedure: remittal for grant
	23.06.2004	Date of oral proceedings
Divisional application(s)	EP02017132.8 / EP1281770
Opposition(s)	22.06.2006	No opposition filed within time limit [2006/35]
Fees paid	Renewal fee
	07.03.1996	Renewal fee patent year 03
	07.03.1997	Renewal fee patent year 04
	05.03.1998	Renewal fee patent year 05
	04.03.1999	Renewal fee patent year 06
	06.03.2000	Renewal fee patent year 07
	05.03.2001	Renewal fee patent year 08
	04.03.2002	Renewal fee patent year 09
	05.03.2003	Renewal fee patent year 10
	04.03.2004	Renewal fee patent year 11
	04.03.2005	Renewal fee patent year 12
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	NL	21.09.2005
	[2006/22]
Documents cited:	Search	[ ] - No further relevant documents disclosed
	International search	[X]WO9116457 (COLD SPRING HARBOR LAB [US]);
		[Y]US5190931 (INOUYE MASAYORI [US]);
		[X] - R. OBERNOLTE ET AL., "The cDNA of a Human Lymphocyte Cyclic-AMP Phosphodiesterase (PDE IV) Reveals a Multigene Family", GENE, (1993), vol. 129, pages 239 - 247, XP002947900 DOI: http://dx.doi.org/10.1016/0378-1119(93)90274-7
		[XP] - BOLGER, G. ET AL., "A Family of Human Phosphodiesterases Homologous to the Dunce Learning and Memory Gene Product of Drosophila Melanogaster are Potential Targets for Antidepressant Drugs", MOLECULAR AND CELLULAR BIOLOGY, (199310), vol. 13, no. 10, pages 6558 - 6571, XP000566626
		[XP] - MCLAUGHLIN, M. M. ET AL, "A Low-Km, Rolipram-Sensitive, cAMP-Specific Phosphodiesterase from Human Brain", JOURNAL OF BIOLOGICAL CHEMISTRY, (19930325), vol. 268, no. 9, pages 6470 - 6476, XP002961426
		[Y] - ODELL, W.D. ET AL., Principles of competitive protein-binding assays, JOHN WILEY & SONS (N.Y.), (1983), pages 243 - 254, XP002961427
		[Y] - P.M. MAURER ET AL., "Proteins and Polypeptides as Antigens", METHODS IN ENZYMOLOGY, (1980), vol. 70, pages 49 - 52, XP002961428
		[Y] - J.R. MURPHY ET AL., "Genetic Construction, Expression and Melanoma-Selective Cytotoxicity of a Diphtheria Toxin-Related Alpha-Melanocyte-Stimulating Hormone Fusion Protein", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, (198611), vol. 83, pages 8258 - 8262, XP002961429 DOI: http://dx.doi.org/10.1073/pnas.83.21.8258
		[X] - G. DENT ET AL., "Inhibition of Eosinophil Cyclic Nucleotide PDE Activity and Opsonised Zymosan-Stimulated Respiratory Burst by 'Type-IV'-Selective PDE Inhibitors", BRITIH JOURNAL OF PHARMACOLOGY, (1991), vol. 103, pages 1339 - 1346, XP002961430
	Examination	- HOUSLAY M.D. ET AL, "The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions", ADVANCES IN PHARMACOLOGY, (1998), vol. 44, pages 225 - 342, XP000926592
		- SHAKUR Y. ET AL, "Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram", BIOCHEM. JOURNAL, (19930615), vol. 292, pages 677 - 686
		- SWINNEN J.V. ET AL, "Attenuation of cAMP-mediated responses in MA-10 Leydig tumor cells by genetic manipulation of a cAMP-phosphodiesterase", JOURNAL OF BIOLOGICAL CHEMISTRY, (19920805), vol. 266, no. 22, pages 14383 - 14389
		- GIEMBYCZ M.A., "Phosphodiesterase 4 inhibitors and the treatment of asthma", DRUGS, (200002), vol. 59, no. 2, pages 193 - 212
		- MANNING C.S. ET AL, "Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B", BRITISH JOURNAL OF PHARMACOLOGY, (1999), vol. 128, pages 1393 - 1398
		- HUSTON E. ET AL, "Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3", BIOCHEMICAL JOURNAL, (1997), vol. 328, pages 549 - 558
		- NELSON D.R., "Cytochrome P450 and the individuality of species", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (19990901), vol. 369, no. 1, pages 1 - 10
		- LAPIDOT M. ET AL, "Mouse-human orthology relationships in an olfactory receptor gene cluster", GENOMICS, (2001), vol. 71, doi:doi:10.1006/geno.2000.6431, pages 296 - 306, XP004432293 DOI: http://dx.doi.org/10.1006/geno.2000.6431
		- DEHAL P. ET AL, "Human chromosome 19 and related regions in mouse: Conservative and lineage-specific evolution", SCIENCE, (20010706), vol. 293, no. 5527, pages 104 - 111
		- SOUNESS J.E. ET AL, "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors", IMMUNOCPHARMACOLOGY, (2000), vol. 47, doi:doi:10.1016/S0162-3109(00)00185-5, pages 127 - 162, XP002325705 DOI: http://dx.doi.org/10.1016/S0162-3109(00)00185-5
		- DONG X. ET AL, "A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons", CELL, (20010907), vol. 106, doi:doi:10.1016/S0092-8674(01)00483-4, pages 619 - 632, XP002287771 DOI: http://dx.doi.org/10.1016/S0092-8674(01)00483-4
		- WANG P. ET AL, "Phosphodiesterase 4B2 is the predominant phoshodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils", MOLECULAR PHARMACOLOGY, (1999), vol. 56, pages 170 - 174, XP001015640
		- BAILLIE G.S. ET AL, "Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activiry of PDE4 cyclic AMP-specific phosphodiesterases", BRITISH JOURNAL OF PHARMACOLOGY, (2000), vol. 131, pages 811 - 819
		- BEAVO J.A.; REIFSNYDER D.H., "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", TRENDS IN PHARMACOLOGICAL SCIENCES, (199004), vol. 11, doi:doi:10.1016/0165-6147(90)90066-H, pages 150 - 155, XP023855291 DOI: http://dx.doi.org/10.1016/0165-6147(90)90066-H
		- SWINNEN J.V. ET AL, "Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat sertoli cell", JOURNAL OF BIOLOGICAL CHEMISTRY, (19910925), vol. 266, no. 27, pages 18370 - 18377
		- WAXMAN D.J., "P450 gene induction by structurally diverso xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (19990901), vol. 369, no. 1, pages 11 - 23
		- LIVI G.P. ET AL, "Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase", MOLECULAR AND CELLULAR BIOLOGY, (199006), vol. 10, no. 6, pages 2678 - 2686, XP002107018
		- COLICELLI J. ET AL, "Expression of three mammalian cDNAs that interfere with RAS function in Saccharomyces cerevisiae", GENETICS, (199104), vol. 88, doi:doi:10.1073/pnas.88.7.2913, pages 2913 - 2917, XP002087363 DOI: http://dx.doi.org/10.1073/pnas.88.7.2913
		- COLICELLI J. ET AL, "Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase", PNAS, (198905), vol. 86, no. 10, doi:doi:10.1073/pnas.86.10.3599, pages 3599 - 3603, XP000026470 DOI: http://dx.doi.org/10.1073/pnas.86.10.3599

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p